Similarly, previous studies have demonstrated that the serum levels of RIPK3 were higher in 10 patients with COVID-19 and ARDS than in six with mild diseases, suggesting that RIPK3-mediated signal is associated with ARDS development in patients with COVID-19 (Nakamura et al., 2020). The gene discussed is RIPK3; the disease is COVID-19.